Adial Pharmaceuticals entered into a Purchase Agreement allowing it to sell up to $5 million in shares to Alumni Capital, potentially increasing to $10 million, while terminating a previous agreement with the same entity. The company can control the timing and amount of sales, with proceeds intended for strategic opportunities and working capital.